Platinum Priority Reply from

Pharma Web site. http://www.astellas.com/en/corporate/news/ detail/post.html. [5] De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364: 1995–2005. [6] Xtandi prescribing information. Astellas Web site. http://www. astellas.us/docs/us/12A005-ENZ-WPI.pdf. [7] De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised openlabel trial. Lancet 2010;376:1147–54. [8] Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363: 411–22. [9] Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008;27:3576–86. [10] Inoki K, Zhu T, Guan K-L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003;115:577–90. [11] Akinyeke T, Matsumura S, Wang X, et al. Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis 2013;34: 2823–32.

[1]  M. Gleave,et al.  Insulin increases de novo steroidogenesis in prostate cancer cells. , 2011, Cancer research.

[2]  Sarat Chandarlapaty,et al.  Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. , 2011, Cancer cell.

[3]  V. Njar,et al.  Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR , 2010, British Journal of Cancer.

[4]  J. Patard,et al.  Thirty-day mortality after nephrectomy: clinical implications for informed consent. , 2009, European urology.

[5]  K. Bensalah,et al.  Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. , 2009, European urology.

[6]  P. Kallidonis,et al.  Laparoscopic or open nephroureterectomy: which is the more efficient way to go? , 2009, European urology.

[7]  Y. Lotan,et al.  Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration , 2009, Cancer.

[8]  J. Patard,et al.  Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. , 2009, Urology.

[9]  F. Saad,et al.  Survival after radical prostatectomy and radiotherapy for prostate cancer: a population-based study. , 2009, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[10]  K. Bensalah,et al.  Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  K. Bensalah,et al.  Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph‐node density , 2009, BJU international.

[12]  J. Patard,et al.  Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study. , 2008, Urology.

[13]  Gauri Sabnis,et al.  Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro , 2008, Molecular Cancer Therapeutics.

[14]  J. Riedemann,et al.  IGF1R signalling and its inhibition. , 2006, Endocrine-related cancer.

[15]  L. Ellison,et al.  Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. , 2000, The Journal of urology.